Hologic Inc. has announced new data from a clinical study evaluating its Genius AI Detection solution, an AI-powered mammography technology. The retrospective analysis, conducted at Massachusetts General Hospital and published in the American Journal of Roentgenology, reviewed 7,500 digital breast tomosynthesis screening exams performed between 2016 and 2019. The study found that among 100 false-negative cases-mammograms initially interpreted as negative but followed by a breast cancer diagnosis within a year-the Genius AI Detection solution flagged approximately one-third (32%) as containing suspicious areas, correctly identifying the location where cancer was later diagnosed. The study's results have already been presented. Study limitations include its single-center design, predominantly Caucasian patient population, and lack of evaluation of patient outcomes or integration into clinical workflows.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hologic Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251216784478) on December 16, 2025, and is solely responsible for the information contained therein.
Comments